BlackRock
CMTA

BlackRock’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

BlackRock’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-354,941
Closed -$5.38M – 5133
2018
Q1 		$5.38M Sell
354,941
-1,659
-0.5% -$27K ﹤0.01% 3400
2017
Q4 		$6.77M Buy
356,600
+500
+0.1% +$8.37K ﹤0.01% 3331
2017
Q3 		$6.01M Buy
+356,100
New +$5.82M ﹤0.01% 3412

Other funds holding CMTA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

BlackRock's CMTA Position: Q2 2018 in Review

BlackRock sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q2 2018, closing a stake of 354,941 shares — an estimated $5.38M sold.

BlackRock first reported a position in CMTA in Q3 2017 and held it in 3 quarters. The position peaked at $6.77M in Q4 2017. 29 funds tracked by Wall St. Rank hold CMTA as of Q2 2018.

  • BlackRock reported no remaining Clementia Pharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
  • BlackRock sold 354,941 Clementia Pharmaceuticals Inc. shares in Q2 2018, an estimated $5.38M.
  • BlackRock first reported a position in Clementia Pharmaceuticals Inc. in Q3 2017 and held it in 3 quarters.
  • BlackRock's Clementia Pharmaceuticals Inc. position peaked at $6.77M in Q4 2017.
  • 29 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q2 2018.

Based on BlackRock's 13F filing for Q2 2018, filed 9 Aug 2018.